BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 25963410)

  • 1. Multiple oncogenic mutations related to targeted therapy in nasopharyngeal carcinoma.
    Zhang JW; Qin T; Hong SD; Zhang J; Fang WF; Zhao YY; Yang YP; Xue C; Huang Y; Zhao HY; Ma YX; Hu ZH; Huang PY; Zhang L
    Chin J Cancer; 2015 Apr; 34(4):177-83. PubMed ID: 25963410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
    Villaruz LC; Socinski MA; Abberbock S; Berry LD; Johnson BE; Kwiatkowski DJ; Iafrate AJ; Varella-Garcia M; Franklin WA; Camidge DR; Sequist LV; Haura EB; Ladanyi M; Kurland BF; Kugler K; Minna JD; Bunn PA; Kris MG
    Cancer; 2015 Feb; 121(3):448-56. PubMed ID: 25273224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.
    Chaft JE; Arcila ME; Paik PK; Lau C; Riely GJ; Pietanza MC; Zakowski MF; Rusch V; Sima CS; Ladanyi M; Kris MG
    Mol Cancer Ther; 2012 Feb; 11(2):485-91. PubMed ID: 22135231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detecting the spectrum of multigene mutations in non-small cell lung cancer by Snapshot assay.
    Su J; Zhang XC; An SJ; Zhong WZ; Huang Y; Chen SL; Yan HH; Chen ZH; Guo WB; Huang XS; Wu YL
    Chin J Cancer; 2014 Jul; 33(7):346-50. PubMed ID: 24823994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer.
    Gasch C; Bauernhofer T; Pichler M; Langer-Freitag S; Reeh M; Seifert AM; Mauermann O; Izbicki JR; Pantel K; Riethdorf S
    Clin Chem; 2013 Jan; 59(1):252-60. PubMed ID: 23136247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of intratumoral heterogeneity of oncogenic driver mutations in surgically-resected lung adenocarcinoma: implications of percutaneous biopsy-based molecular assay for target-directed therapy.
    Kim HK; Lee HY; Choi YL; Choi SJ; Choi H; Lee J; Han J; Ahn MJ; Lee KS; Kim J
    Anticancer Res; 2014 Feb; 34(2):707-14. PubMed ID: 24511003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer.
    Lin JJ; Ritterhouse LL; Ali SM; Bailey M; Schrock AB; Gainor JF; Ferris LA; Mino-Kenudson M; Miller VA; Iafrate AJ; Lennerz JK; Shaw AT
    J Thorac Oncol; 2017 May; 12(5):872-877. PubMed ID: 28088512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential of PIK3CA, KRAS, BRAF, and APC hotspot mutations as a non-invasive detection method for colorectal cancer.
    Alizadeh-Sedigh M; Mahmoodzadeh H; Fazeli MS; Haddadi-Aghdam M; Teimoori-Toolabi L
    Mol Cell Probes; 2022 Jun; 63():101807. PubMed ID: 35296442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concurrent oncogene mutation profile in Chinese patients with stage Ib lung adenocarcinoma.
    Wen YS; Cai L; Zhang XW; Zhu JF; Zhang ZC; Shao JY; Zhang LJ
    Medicine (Baltimore); 2014 Dec; 93(29):e296. PubMed ID: 25546673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncogenic mutations and microsatellite instability phenotype predict specific anatomical subsite in colorectal cancer patients.
    Corso G; Pascale V; Flauti G; Ferrara F; Marrelli D; Roviello F
    Eur J Hum Genet; 2013 Dec; 21(12):1383-8. PubMed ID: 23572025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix.
    Wright AA; Howitt BE; Myers AP; Dahlberg SE; Palescandolo E; Van Hummelen P; MacConaill LE; Shoni M; Wagle N; Jones RT; Quick CM; Laury A; Katz IT; Hahn WC; Matulonis UA; Hirsch MS
    Cancer; 2013 Nov; 119(21):3776-83. PubMed ID: 24037752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.
    Rossing HH; Grauslund M; Urbanska EM; Melchior LC; Rask CK; Costa JC; Skov BG; Sørensen JB; Santoni-Rugiu E
    BMC Res Notes; 2013 Nov; 6():489. PubMed ID: 24279718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hotspot mutations in common oncogenes are infrequent in nasopharyngeal carcinoma.
    Jiang N; Liu N; Yang F; Zhou Q; Cui R; Jiang W; He Q; Li W; Guo Y; Zeng J; Yun J; Chen X; Zhou B; Sun Y; Wang H; Chen ZG; Ma J
    Oncol Rep; 2014 Oct; 32(4):1661-9. PubMed ID: 25109408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutational analyses of multiple oncogenic pathways in intraductal papillary mucinous neoplasms of the pancreas.
    Schönleben F; Allendorf JD; Qiu W; Li X; Ho DJ; Ciau NT; Fine RL; Chabot JA; Remotti HE; Su GH
    Pancreas; 2008 Mar; 36(2):168-72. PubMed ID: 18376308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
    Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
    Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.
    Li H; Pan Y; Li Y; Li C; Wang R; Hu H; Zhang Y; Ye T; Wang L; Shen L; Sun Y; Chen H
    Lung Cancer; 2013 Jan; 79(1):8-13. PubMed ID: 23098378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncogene alterations in endometrial carcinosarcomas.
    Biscuola M; Van de Vijver K; Castilla MÁ; Romero-Pérez L; López-García MÁ; Díaz-Martín J; Matias-Guiu X; Oliva E; Palacios Calvo J
    Hum Pathol; 2013 May; 44(5):852-9. PubMed ID: 23199529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive genomic profiling of different subtypes of nasopharyngeal carcinoma reveals similarities and differences to guide targeted therapy.
    Ali SM; Yao M; Yao J; Wang J; Cheng Y; Schrock AB; Chirn GW; Chen H; Mu S; Gay L; Elvin JA; Suh J; Miller VA; Stephens PJ; Ross JS; Wang K
    Cancer; 2017 Sep; 123(18):3628-3637. PubMed ID: 28581676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between Programmed Death Ligand-1(PD-L1) Expression and Driver Gene Mutations in Non-Small Cell Lung Carcinoma- Adenocarcinoma Phenotype.
    Pandey RK; Shukla S; Husain N; Islam MH; Hadi R; Kant Tripathi S; Singhal A
    Asian Pac J Cancer Prev; 2022 Jan; 23(1):131-142. PubMed ID: 35092381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer.
    Kawazoe A; Shitara K; Fukuoka S; Kuboki Y; Bando H; Okamoto W; Kojima T; Fuse N; Yamanaka T; Doi T; Ohtsu A; Yoshino T
    BMC Cancer; 2015 Apr; 15():258. PubMed ID: 25886136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.